Free Trial
NYSE:DPLO

Diplomat Pharmacy (DPLO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.00
$4.01
50-Day Range
$4.00
$4.00
52-Week Range
$2.43
$14.46
Volume
744,968 shs
Average Volume
545,194 shs
Market Capitalization
$304 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DPLO stock logo

About Diplomat Pharmacy Stock (NYSE:DPLO)

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

DPLO Stock News Headlines

This ticker outperformed Bitcoin by nearly 20x last time
Before you buy the newly approved Bitcoin ETFs… Take a look at this “Better than Bitcoin ticker” you can buy in any regular brokerage account. Why? Because it’s been shown to outperform Bitcoin by 10X or more during the past four bull runs… For example, while Bitcoin surged 985% during the last bull run in 2021…
This ticker outperformed Bitcoin by nearly 20x last time
Before you buy the newly approved Bitcoin ETFs… Take a look at this “Better than Bitcoin ticker” you can buy in any regular brokerage account. Why? Because it’s been shown to outperform Bitcoin by 10X or more during the past four bull runs… For example, while Bitcoin surged 985% during the last bull run in 2021…
Diplomat Cocktail
See More Headlines
Receive DPLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diplomat Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
7/15/2024

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Fax
N/A
Employees
2,335
Year Founded
N/A

Profitability

Net Income
$-302,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.49 billion
Cash Flow
$4.60 per share
Book Value
$6.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$304 million
Optionable
Optionable
Beta
0.82
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Brian Thomas Griffin (Age 60)
    CEO & Chairman
  • Mr. Philip R. Hagerman (Age 67)
    Co-Founder & Chairman Emeritus
  • Mr. Daniel Paul Davison
    CFO & Treasurer
  • Mr. Dave Loschinskey (Age 48)
    Chief Operating Officer
  • Ms. Terri Anne Powers
    VP of Investor Relations

DPLO Stock Analysis - Frequently Asked Questions

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $2.15. The business's quarterly revenue was down 5.3% compared to the same quarter last year.

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Cara Therapeutics (CARA), Karyopharm Therapeutics (KPTI), General Electric (GE), OPKO Health (OPK) and ServiceSource International (SREV).

This page (NYSE:DPLO) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners